Key result
While B-type natriuretic peptides and cardiac troponin are established in cardiovascular disease, there remains an unmet need for validated biomarkers of inflammation, oxidative stress, and fibrosis.
This review emphasizes the need for novel circulating biomarkers to guide emerging targeted therapies in cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Gaps persist in guiding targeted therapies; leaves open validation of novel biomarkers for inflammation and fibrosis.
Mark Richards (2018) conducted a review in Cardiovascular disease. Circulating biomarkers was evaluated. While B-type natriuretic peptides and cardiac troponin are established in cardiovascular disease, there remains an unmet need for validated biomarkers of inflammation, oxidative stress, and fibrosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: